Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avastin Bid For Full Approval In Metastatic Breast Cancer May Require Another Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA says Roche/Genentech's follow-up studies did not produce clinically meaningful results using the progression-free survival endpoint.

You may also be interested in...



Avastin Breast Cancer Approval Debate Pits Clinical Benefit Versus Statistics

The Oncology Drugs Advisory Committee's vote against full approval of Roche's Avastin (bevacizumab) for first-line treatment of metastatic breast cancer hinged to a large degree on its feeling that the drug did not delay disease progression long enough to be clinically meaningful

Avastin Breast Cancer Approval Debate Pits Clinical Benefit Versus Statistics

The Oncology Drugs Advisory Committee's vote against full approval of Roche's Avastin (bevacizumab) for first-line treatment of metastatic breast cancer hinged to a large degree on its feeling that the drug did not delay disease progression long enough to be clinically meaningful

Avastin's Last Hope For Breast Cancer Claim May Be Subpopulations

FDA advisory committee votes to remove the breast cancer treatment indication from the Genentech drug's label after failed confirmatory trial, but two more studies are on their way.

Related Content

Topics

UsernamePublicRestriction

Register

PS070908

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel